Boston Scientific’s $1.07bn asset transaction deal with Lumenis was the medical devices industry’s biggest cross border deal of Q1 2021 as cross border deals worth $6.67bn were announced globally in the quarter, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the image source into your website to display the chart.
The value marked a decrease of 5.5% over the previous quarter and a drop of 16.4% when compared with the last four-quarter average of $7.98bn.
In terms of number of cross border deals, the sector saw a rise of 17.14% with 135 deals in Q1 2021 against the average of 115.25 deals in the last four-quarters.
In value terms, North America led the activity with cross border deals worth $2.73bn.
medical devices industry cross border deals in Q1 2021: Top deals
The top five medical devices industry cross border deals accounted for 53.8% of the overall value during Q1 2021.
The combined value of the top five cross border deals stood at $3.59bn, against the overall value of $6.67bn recorded for the quarter.
The top five medical devices industry cross border deals of Q1 2021 tracked by GlobalData were:
1) Boston Scientific’s $1.07bn asset transaction deal with Lumenis
2) The $880.85m asset transaction with Novasep Holding by Thermo Fisher Scientific
3) Koninklijke Philips’ $635m acquisition of Capsule Technologies
4) The $591m acquisition of Oxford Immunotec by PerkinElmer
5) Savaria’s acquisition of Handicare Group for $409.7m.
Related Companies
Verdict deals analysis methodology
This analysis considers only announced and completed cross border deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.